Dr Adnan Nagrial

BMedSci MBBS PhD FRACP
Clinical Associate Professor
Westmead Clinical School

Telephone +61 2 8890 5200
Fax +61 2 8890 6391

Website Personal website

Map

Biographical details

Adnan Nagrial is a Medical Oncologist and Clinical Associate Professor at The University of Sydney, and Westmead and Blacktown Hospitals. His clinical interest is in Gastrointestinal and Thoracic Cancers and he also has an interest in Phase 1 drug development. He is involved in both clinical and translational research.

Keywords

Lung cancer; Cancer; Colorectal cancers

Clinical Specialty

Oncology

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Chin, V., Nagrial, A., Sjoquist, K., O�Connor, C., Chantrill, L., Biankin, A., Scholten, R., Yip, D. (2018). Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database of Systematic Reviews, 3, 1-126. [More Information]
  • Pokorny, A., Chin, V., Nagrial, A., Yip, D., Chantrill, L. (2018). Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. Internal Medicine Journal, 48(6), 637-644. [More Information]
  • Chou, A., Froio, D., Nagrial, A., Parkin, A., Murphy, K., Chin, V., Wohl, D., Steinmann, A., Stark, R., Drury, A., Clarke, S., Gill, A., et al (2018). Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut, 67(12), 2142-2155. [More Information]
  • Parkin, A., Man, J., Chou, A., Nagrial, A., Samra, J., Gill, A., Timpson, P., Pajic, M. (2018). The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases, 6(4), 1-18. [More Information]
  • Karikios, D., Chim, L., Martin, A., Nagrial, A., Howard, K., Salkeld, G., Stockler, M. (2017). Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia. Internal Medicine Journal, 47(4), 400-407. [More Information]
  • Vennin, C., Chin, V., Warren, S., Lucas, M., Herrmann, D., Magenau, A., Melenec, P., Walters, S., del Monte-Nieto, G., Conway, J., Jain, R., Weninger, W., Johns, A., Gill, A., et al (2017). Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 9(384), 1-17. [More Information]
  • Janssen, A., Shaw, T., Nagrial, A., Pene, C., Rabbets, M., Carlino, M., Zachulski, C., Phillips, J., Birnbaum, R., Gandhi, T., Harnett, P. (2016). An Online Learning Module to Increase Self-Efficacy and Involvement in Care for Patients With Advanced Lung Cancer: Research Protocol. JMIR Research Protocols, 5(3), 1-8. [More Information]
  • Bailey, P., Chang, D., Nones, K., Johns, A., Patch, A., Gingras, M., Miller, D., Christ, A., Bruxner, T., Quinn, M., Samra, J., Kench, J., Gill, A., et al (2016). Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), 47-52. [More Information]
  • Humphrey, E., Su, S., Nagrial, A., Hochgrafe, F., Pajic, M., Lehrbach, G., Parton, R., Yap, A., Horvath, L., Chang, D., et al (2016). Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. Molecular and Cellular Proteomics, 15(8), 2671-2685. [More Information]
  • Sabanathan, D., Nagrial, A., Chin, V. (2016). The changing landscape of systemic therapy in advanced pancreatic cancer. Cancer Forum, 40(1), 53-58.
  • Carlino, M., Kwan, V., Miller, D., Saunders, C., Yip, D., Nagrial, A., Tomlinson, J., Grimmond, S., Scolyer, R., Kefford, R., Long, G., et al (2015). New RAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma. Journal of Clinical Oncology, 33(11), e52-E56. [More Information]
  • Carlino, M., Fung, C., Shahheydari, H., Todd, J., Boyd, S., Irvine, M., Nagrial, A., Scolyer, R., Kefford, R., Long, G., Rizos, H. (2015). Pre-existing MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. Clinical Cancer Research, 21(1), 98-105. [More Information]
  • Chantrill, L., Nagrial, A., Watson, C., Johns, A., Martyn-Smith, M., Simpson, S., Mead, S., Jones, M., Samra, J., Gill, A., Chin, V., Sebastian, L., Sjoquist, K., Yip, S., Pavlakis, N., Grimison, P., Simes, R., et al (2015). Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clinical Cancer Research, 21(9), 2029-2037. [More Information]
  • Chin, V., Nagrial, A., Chou, A., Biankin, A., Gill, A., Timpson, P., Pajic, M. (2015). Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. Expert Reviews in Molecular Medicine, 17, 1-14. [More Information]
  • Nagrial, A., Chin, V., Sjoquist, K., Pajic, M., Horvath, L., Biankin, A., Yip, D. (2015). Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Critical Reviews in Oncology / Hematology (online), 96(3), 483-497. [More Information]
  • Nagrial, A., Chang, D., Nguyen, N., Johns, A., Chantrill, L., Humphris, J., Chin, V., Samra, J., Gill, A., Pajic, M., Kench, J., et al (2014). Adjuvant chemotherapy in elderly patients with pancreatic cancer. British Journal of Cancer, 110(2), 313-319. [More Information]
  • Humphris, J., Johns, A., Simpson, S., Cowley, M., Pajic, M., Chang, D., Nagrial, A., Chin, V., Chantrill, L., Pinese, M., Gill, A., Samra, J., Kench, J., et al (2014). Clinical and pathologic features of familial pancreatic cancer. Cancer, 120(23), 3669-3675. [More Information]
  • Al-Ejeh, F., Pajic, M., Shi, W., Kalimutho, M., Miranda, M., Nagrial, A., Chou, A., Biankin, A., Grimmond, S., et al (2014). Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 20(12), 3187-3197. [More Information]
  • Sjoquist, K., Chin, V., Chantrill, L., O'Connor, C., Hemmings, C., Chang, D., Chou, A., Pajic, M., Johns, A., Nagrial, A., et al (2014). Personalising pancreas cancer treatment: When tissue is the issue. World Journal of Gastroenterology, 20(24), 7849-7863. [More Information]
  • Chou, A., Waddell, N., Cowley, M., Gill, A., Chang, D., Patch, A., Nones, K., Wu, J., Pinese, M., Johns, A., Toon, C., et al (2013). Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Medicine, 5(8), 1-11. [More Information]
  • Chang, D., Jamieson, N., Johns, A., Scarlett, C., Pajic, M., Chou, A., Pinese, M., Humphris, J., Jones, M., Toon, C., Samra, J., Kench, J., Gill, A., et al (2013). Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. Journal of Clinical Oncology, 31(10), 1348-1356. [More Information]
  • Humphris, J., Chang, D., Johns, A., Scarlett, C., Pajic, M., Jones, M., Colvin, E., Nagrial, A., Chin, V., Chantrill, L., Samra, J., Gill, A., Kench, J., et al (2012). The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Annals of Oncology, 23(7), 1713-1722. [More Information]
  • Nagrial, A., Horvath, L. (2010). Bone disease in prostate cancer. Asia-Pacific Journal of Clinical Oncology, 6(1), 3-4. [More Information]

2018

  • Chin, V., Nagrial, A., Sjoquist, K., O�Connor, C., Chantrill, L., Biankin, A., Scholten, R., Yip, D. (2018). Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database of Systematic Reviews, 3, 1-126. [More Information]
  • Pokorny, A., Chin, V., Nagrial, A., Yip, D., Chantrill, L. (2018). Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. Internal Medicine Journal, 48(6), 637-644. [More Information]
  • Chou, A., Froio, D., Nagrial, A., Parkin, A., Murphy, K., Chin, V., Wohl, D., Steinmann, A., Stark, R., Drury, A., Clarke, S., Gill, A., et al (2018). Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut, 67(12), 2142-2155. [More Information]
  • Parkin, A., Man, J., Chou, A., Nagrial, A., Samra, J., Gill, A., Timpson, P., Pajic, M. (2018). The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases, 6(4), 1-18. [More Information]

2017

  • Karikios, D., Chim, L., Martin, A., Nagrial, A., Howard, K., Salkeld, G., Stockler, M. (2017). Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia. Internal Medicine Journal, 47(4), 400-407. [More Information]
  • Vennin, C., Chin, V., Warren, S., Lucas, M., Herrmann, D., Magenau, A., Melenec, P., Walters, S., del Monte-Nieto, G., Conway, J., Jain, R., Weninger, W., Johns, A., Gill, A., et al (2017). Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 9(384), 1-17. [More Information]

2016

  • Janssen, A., Shaw, T., Nagrial, A., Pene, C., Rabbets, M., Carlino, M., Zachulski, C., Phillips, J., Birnbaum, R., Gandhi, T., Harnett, P. (2016). An Online Learning Module to Increase Self-Efficacy and Involvement in Care for Patients With Advanced Lung Cancer: Research Protocol. JMIR Research Protocols, 5(3), 1-8. [More Information]
  • Bailey, P., Chang, D., Nones, K., Johns, A., Patch, A., Gingras, M., Miller, D., Christ, A., Bruxner, T., Quinn, M., Samra, J., Kench, J., Gill, A., et al (2016). Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), 47-52. [More Information]
  • Humphrey, E., Su, S., Nagrial, A., Hochgrafe, F., Pajic, M., Lehrbach, G., Parton, R., Yap, A., Horvath, L., Chang, D., et al (2016). Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. Molecular and Cellular Proteomics, 15(8), 2671-2685. [More Information]
  • Sabanathan, D., Nagrial, A., Chin, V. (2016). The changing landscape of systemic therapy in advanced pancreatic cancer. Cancer Forum, 40(1), 53-58.

2015

  • Carlino, M., Kwan, V., Miller, D., Saunders, C., Yip, D., Nagrial, A., Tomlinson, J., Grimmond, S., Scolyer, R., Kefford, R., Long, G., et al (2015). New RAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma. Journal of Clinical Oncology, 33(11), e52-E56. [More Information]
  • Carlino, M., Fung, C., Shahheydari, H., Todd, J., Boyd, S., Irvine, M., Nagrial, A., Scolyer, R., Kefford, R., Long, G., Rizos, H. (2015). Pre-existing MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. Clinical Cancer Research, 21(1), 98-105. [More Information]
  • Chantrill, L., Nagrial, A., Watson, C., Johns, A., Martyn-Smith, M., Simpson, S., Mead, S., Jones, M., Samra, J., Gill, A., Chin, V., Sebastian, L., Sjoquist, K., Yip, S., Pavlakis, N., Grimison, P., Simes, R., et al (2015). Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clinical Cancer Research, 21(9), 2029-2037. [More Information]
  • Chin, V., Nagrial, A., Chou, A., Biankin, A., Gill, A., Timpson, P., Pajic, M. (2015). Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. Expert Reviews in Molecular Medicine, 17, 1-14. [More Information]
  • Nagrial, A., Chin, V., Sjoquist, K., Pajic, M., Horvath, L., Biankin, A., Yip, D. (2015). Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Critical Reviews in Oncology / Hematology (online), 96(3), 483-497. [More Information]

2014

  • Nagrial, A., Chang, D., Nguyen, N., Johns, A., Chantrill, L., Humphris, J., Chin, V., Samra, J., Gill, A., Pajic, M., Kench, J., et al (2014). Adjuvant chemotherapy in elderly patients with pancreatic cancer. British Journal of Cancer, 110(2), 313-319. [More Information]
  • Humphris, J., Johns, A., Simpson, S., Cowley, M., Pajic, M., Chang, D., Nagrial, A., Chin, V., Chantrill, L., Pinese, M., Gill, A., Samra, J., Kench, J., et al (2014). Clinical and pathologic features of familial pancreatic cancer. Cancer, 120(23), 3669-3675. [More Information]
  • Al-Ejeh, F., Pajic, M., Shi, W., Kalimutho, M., Miranda, M., Nagrial, A., Chou, A., Biankin, A., Grimmond, S., et al (2014). Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 20(12), 3187-3197. [More Information]
  • Sjoquist, K., Chin, V., Chantrill, L., O'Connor, C., Hemmings, C., Chang, D., Chou, A., Pajic, M., Johns, A., Nagrial, A., et al (2014). Personalising pancreas cancer treatment: When tissue is the issue. World Journal of Gastroenterology, 20(24), 7849-7863. [More Information]

2013

  • Chou, A., Waddell, N., Cowley, M., Gill, A., Chang, D., Patch, A., Nones, K., Wu, J., Pinese, M., Johns, A., Toon, C., et al (2013). Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Medicine, 5(8), 1-11. [More Information]
  • Chang, D., Jamieson, N., Johns, A., Scarlett, C., Pajic, M., Chou, A., Pinese, M., Humphris, J., Jones, M., Toon, C., Samra, J., Kench, J., Gill, A., et al (2013). Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. Journal of Clinical Oncology, 31(10), 1348-1356. [More Information]

2012

  • Humphris, J., Chang, D., Johns, A., Scarlett, C., Pajic, M., Jones, M., Colvin, E., Nagrial, A., Chin, V., Chantrill, L., Samra, J., Gill, A., Kench, J., et al (2012). The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Annals of Oncology, 23(7), 1713-1722. [More Information]

2010

  • Nagrial, A., Horvath, L. (2010). Bone disease in prostate cancer. Asia-Pacific Journal of Clinical Oncology, 6(1), 3-4. [More Information]

To update your profile click here. For support on your academic profile contact .